Isepamicin
| Clinical data | |
|---|---|
| Other names | Isepamycin (2S)-3-Amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-[(3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-2-[(3R,4R,5R)-3,5-dihydroxy-5-methyl-4-methylaminooxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxypropanamide | 
| AHFS/Drugs.com | International Drug Names | 
| ATC code | |
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.055.567 | 
| Chemical and physical data | |
| Formula | C22H43N5O12 | 
| Molar mass | 569.609 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (what is this?) (verify) | |
Isepamicin (isepamycin) is an aminoglycoside antibiotic.
It was patented in 1973 and approved for medical use in 1988. It has been identified by the World Health Organization as a Critically Important Antimicrobial for human use.